Logo for Novavax Inc

Novavax Investor Relations Material

Latest events

Logo for Novavax Inc

Q4 2023

Novavax
Logo for Novavax

Q4 2023

28 Feb, 2024
Logo for Novavax

Q3 2023

9 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Segment Data
Access more data
Revenue by
Type
Product sales
Grants
Royalties and other
Expenses by
Financials
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's recombinant nanoparticle vaccine technology is based on its proprietary MVA-VLP platform, which is designed to entrap antigens within its shell while displaying antigens on its surface. The company has clinical, licensed, or in-licensed product candidates in development for the prevention of respiratory syncytial virus (RSV), Middle East respiratory syndrome coronavirus (MERS-CoV), and seasonal influenza viruses, as well as a non-clinical RSV F gene antagonist program. Available products include RespiGam; and Pediatrics Respiratory Influenza Vaccine (RIV) for children. Novavax, Inc. is based in Gaithersburg, Maryland.